Table 4 Estimates of mean survival (months) based on studies of patients with non- squamous histology

REVEL

Ram + Doc (465)

Plac + Doc (447)

 RMS [95% CI]

to 27 mos

13.50 [12.60–14.40]

12.10 [11.20–13.00]

1.39 [0.12–2.67]

 Mean total OS

R_mSext

18.18

14.88

3.31

 Mean total OS

Weibull [95% CI]

15.98 [14.16–18.15]

13.56 [12.00–15.41]

2.42 [−0.20–5.04]

 Mean total OS

Weibull formula

16.98

13.56

2.43

LUME LUNG-1

Nin + Doc (322)

Plac + Doc (336)

 RMS [95% CI]

to 27 mos

14.18 [13.14–15.21]

12.62 [11.65–13.59]

1.55 [0.14–2.97]

 Mean total OS

R_mSext

17.84

14.90

2.94

 Mean total OS

Weibull [95% CI]

17.29 [15.24–19.68]

14.45 [12.88–16.26]

2.84 [0.05–5.63]

 Mean total OS

Weibull formula

17.30

14.45

2.85

Checkmate_057

Nivolumab (292)

Docetaxel (290)

 RMS [95% CI]

to 27 mos

13.93 [12.77–15.09]

11.79 [10.78–12.80]

2.14 [0.61–3.68]

 Mean total OS

R_mSext

18.29

14.72

3.57

 Mean total OS

Weibull [95% CI]

18.04 [15.48–21.07]

13.32 [11.73–15.18]

4.72 [1.44–8.00]

 Mean total OS

Weibull formula

18.13

13.31

4.82

OAK

Atezolizumab (313)

Docetaxel (315)

 RMS [95% CI]

to 27 mos

15.62 [14.5–16.72]

13.07 [11.99–14.15]

2.55 [1.00–4.09]

 Mean total OS

R_mSext

23.76

13.09

10.67

 Mean total OS

Weibull [95% CI]

20.70 [17.64–24.51]

15.02 [13.05–17.43]

5.68 [1.61–9.75]

 Mean total OS

Weibull formula

20.79

15.01

5.77

Hanna

Pemetrexed (205)

Docetaxel (194)

 RMS [95% CI]

to 27 mos

na

na

na

 Mean total OS

R_mSext

12.54

10.72

1.82

 Mean total OS

Weibull [95% CI]

11.88 [10.27–13.82]

10.53 [9.11–12.20]

1.35 [−1.00–3.70]

 Mean total OS

Weibull formula

11.87

10.52

1.35